Subscribe to RSS
DOI: 10.1055/s-0037-1619358
Classifying patients as GOLD A-D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials
Publication History
Publication Date:
21 February 2018 (online)
Introduction:
The 2017 GOLD strategy uses symptoms and exacerbations to class patients as A-D, but no longer includes lung function as the previous strategy did. This has implications for treatment decisions.
Aims and objectives:
To investigate the efficacy of tiotropium+olodaterol (T+O) compared with tiotropium and placebo in patients classed as GOLD A or B using the GOLD 2017 strategy, and compare with the subgroup defined using the 2014 strategy.
Methods:
OTEMTO 1 & 2 (NCT01964352, NCT02006732) were replicate, placebo-controlled Phase III trials: patients with COPD received T+O 5/5 µg, 2.5/5 µg, tiotropium 5 µg orplacebo via the Respimat® device for 12 weeks. SGRQ and transition dyspnoea index (TDI) data from patients with either GOLD 2017 A or B status (using modified Medical Research Council Dyspnoea Scale [mMRC] and exacerbation history) or GOLD 2014 A or B status (using lung function, exacerbation history and mMRC) were analysed.
Results:
More patients are in groups A and B with the 2017 strategy than with the 2014 strategy. T+O and tiotropium were more effective than placebo at improving SGRQ score and TDI score across groups, and the results are similar using the 2017 and 2014 classifications (Tab).
SGRQ total score change from baseline |
Mahler TDI focal score |
|||||||||||
2017 |
2014 |
2017 |
2014 |
|||||||||
n |
Adj mean |
Resp,† n |
n |
Adj mean |
Resp,† n |
n |
Adj mean |
Resp* n |
n |
Adj mean |
Resp * n |
|
(SE) |
(%) |
(SE) |
(%) |
(SE) |
(%) |
(SE) |
(%) |
|||||
GOLD A |
||||||||||||
T+O 5/5 µg |
164 |
-4.26 (0.71) |
79 (48) |
116 |
-2.79 (0.84) |
53 (46) |
164 |
1.73 (0.21) |
84 (51) |
116 |
1.60 (0.25) |
55 (47) |
Tio 5 µg |
168 |
-3.59 (0.70) |
74 (44) |
123 |
-3.29 (0.82) |
52 (42) |
167 |
1.13 (0.21) |
67 (40) |
122 |
1.09 (0.31) |
51 (42) |
Placebo |
156 |
0.19 (0.73) |
49 (31) |
115 |
-0.15 (0.86) |
40 (35) |
156 |
0.20 (0.22) |
42 (27) |
115 |
0.46 (0.31) |
36 (31) |
GOLD B |
||||||||||||
T+O 5/5 µg |
195 |
-5.99 (0.74) |
116 (60) |
108 |
-6.92 (1.00) |
70 (65) |
195 |
1.73 (0.19) |
110 (56) |
108 |
1.73 (0.23) |
62 (57) |
Tio 5 µg |
184 |
-2.45 (0.76) |
74 (40) |
112 |
-1.04 (0.98) |
42 (38) |
185 |
1.03 (0.19) |
75 (41) |
113 |
1.03 (0.23) |
41 (36) |
Placebo |
185 |
-0.70 (0.76) |
59 (32) |
115 |
-1.56 (1.48) |
38 (33) |
185 |
0.03 (0.19) |
46 (25) |
116 |
0.34 (0.23) |
28 (24) |
†Change from baseline ≥4 units; *change from baseline ≥1.0. Adj, adjusted; Resp, responder; SE, standard error; SGRQ, St. George's Respiratory Questionnaire; T+O, tiotropium+olodaterol; TDI, transition dyspnoea index; Tio, tiotropium. |
Conclusions:
More patients are classed as GOLD A or B with the 2017 strategy than with the 2014 strategy but the efficacy conclusions remain the same.
Sponsored by Boehringer Ingelheim.
Previously presented at ERS 2017.
#